Amgen announces presentation of 15 abstracts from cardiovascular pipeline
Amgen announced that it will present 15 abstracts, including data evaluating, an investigational cholesterol-lowering medication, and Corlanor, an investigational drug for chronic heart failure, at the upcoming American College of Cardiology's 64th Annual Scientific Session, being held March 14-16 in San Diego. Repatha is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9, a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol, or "bad" cholesterol, from the blood. Corlanor is an oral drug that acts on the body's cardiac pacemaker to slow the heart rate without negative effects on myocardial contractility or ventricular repolarization. Among the abstracts is a Late-Breaking Clinical Trial presentation of LDL-C lowering and major adverse cardiovascular event data after one year of treatment from the OSLER-1 and -2 studies in the Repatha program, and an oral presentation of long-term data from the OSLER-1 trial evaluating the safety and efficacy of Repatha after two years of treatment. Repatha data presentations also include a pooled safety analysis in over 6,000 patients from Phase 2 and 3 short- and long-term clinical trials. The Phase 3 results from the YUKAWA-2 study evaluating Repatha in combination with statin therapy in Japanese patients with high cardiovascular risk and high cholesterol will also be presented. Additionally, two analyses from the Phase 3 SHIFT study evaluating Corlanor will be presented. These data include an oral presentation on the efficacy profile of Corlanor in patients with chronic heart failure and angina, and a poster on whether the addition of Corlanor to optimized background therapy affects beta blocker usage.
News 
Market Data 
Discover 
